Search results
Martin Hutchings, MD, PhD. Dr. Martin Hutchings received his medical degree and his PhD at the University of Copenhagen, Denmark. He is a staff specialist, Department of Hematology, at the Finsen Centre, National Hospital, Copenhagen University Hospital in Denmark.
Rigshospitalet - Cited by 14,678
Dec 8, 2023 · Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
Martin HUTCHINGS, Senior consultant | Cited by 9,901 | of Rigshospitalet, Copenhagen (rigshospitalet) | Read 243 publications | Contact Martin HUTCHINGS
Nov 5, 2020 · Introduction: Glofitamab (RG6026) is a novel T-cell-engaging, bispecific, full-length antibody with a 2:1 molecular configuration that facilitates bivalent binding to CD20 on B-cells, and monovalent binding to CD3 on T-cells.
- Martin Hutchings, Carmelo Carlo-Stella, Emmanuel Bachy, Fritz C. Offner, Franck Morschhauser, Michae...
- 2020
Jun 20, 2021 · Purpose: Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
Nov 13, 2019 · The 2:1 molecular format of CD20-TCB, which incorporates bivalent binding to CD20 on B cells and monovalent binding to CD3 on T cells, redirects endogenous non-specific T cells to engage and eliminate malignant B cells. CD20-TCB is an investigational agent. Topics:
